The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

NCT ID: NCT03447938

Last Updated: 2024-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-01

Study Completion Date

2028-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MICS CABG (Minimally invasive coronary surgery), where coronary artery bypass grafting (CABG) is completed through a small incision over the left chest, has evolved to become a safe and less invasive alternative to conventional sternotomy CABG. Several observational studies have suggested significantly shorter time to return to physical activity for MICS CABG patients compared to sternotomy CABG patients. A randomized study is warranted to validate these findings, provide higher level of evidence, and potentially lead to changes in practice. The MIST Trial is a multi-centre, prospective, open label, randomized control trial comparing quality of life and recovery in the early post-operative period, between patients undergoing MICS CABG versus patients undergoing sternotomy CABG. Patients referred for isolated CABG for multi-vessel coronary artery disease and deemed technically suitable for sternotomy CABG as well as for MICS CABG are considered for enrollment into the trial. Quality of life questionnaires (The SF-36, Seattle Angina Questionnaire and EQ-5D-5L) will be used to assess the quality of life and recovery in patients undergoing sternotomy CABG or MICS CABG at 1 month, 3 months, 6 months and 12 months follow up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CABG with sternotomy

Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).

Group Type ACTIVE_COMPARATOR

Conventional CABG

Intervention Type PROCEDURE

Coronary artery bypass grafting performed through an incision through the sternum or breastbone.

Minimally-invasive CABG

Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.

Group Type EXPERIMENTAL

MICS CABG

Intervention Type PROCEDURE

Coronary artery bypass grafting performed through small incisions between the ribs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MICS CABG

Coronary artery bypass grafting performed through small incisions between the ribs.

Intervention Type PROCEDURE

Conventional CABG

Coronary artery bypass grafting performed through an incision through the sternum or breastbone.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Minimally invasive coronary artery bypass grafting coronary artery bypass grafting via sternotomy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Angiographically-confirmed multi-vessel coronary artery disease lesions with \>=70% in at least 2 major epicardial vessels in 2 or more coronary artery territories (left anterior descending (LAD), circumflex (CX) and right coronary artery (RCA)) OR lesions \>=50% in the left main (LM)
* Patients who, in the opinion of the investigator, are amenable for coronary surgery through either median sternotomy or minimally-invasive approach.
* Patients who are willing and able to comply with all follow-up study visits.

Exclusion Criteria

* \<18 years of age
* concomitant cardiac procedure with CABG (e.g. valve repair or replacement)
* Previous cardiac surgery, mediastinal irradiation, or significant trauma to the chest
* Contra-indications for MICS CABG, including: severe pectus excavatum; severe pulmonary disease; hemodynamically significant left subclavian stenosis; morbid obesity; severe left ventricular (LV) dysfunction; no adequate PDA or marginal branch target; absence of femoral pulse bilaterally.
* Contraindications for conventional CABG via sternotomy
* Concomitant life-threatening disease likely to limit life expectancy to \<2 years
* Emergency CABG with hemodynamic compromise
* Inability to provide informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

London Health Sciences Centre

OTHER

Sponsor Role collaborator

Heart Center Leipzig - University Hospital

OTHER

Sponsor Role collaborator

Fortis Escorts Heart Institute

OTHER

Sponsor Role collaborator

The Methodist Hospital Research Institute

OTHER

Sponsor Role collaborator

Carolinas Medical Center

OTHER

Sponsor Role collaborator

Gundersen Lutheran Health System

OTHER

Sponsor Role collaborator

Jilin Heart Hospital

OTHER

Sponsor Role collaborator

Far Eastern Memorial Hospital

OTHER

Sponsor Role collaborator

Medtronic

INDUSTRY

Sponsor Role collaborator

Apollo Hospitals Enterprise Limited

OTHER

Sponsor Role collaborator

Fresno Heart and Surgical Hospital

UNKNOWN

Sponsor Role collaborator

Ichinomiya-Nishi Hospital

UNKNOWN

Sponsor Role collaborator

Ottawa Heart Institute Research Corporation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Ruel, MD

Role: PRINCIPAL_INVESTIGATOR

Ottawa Heart Institute Research Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status NOT_YET_RECRUITING

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, United States

Site Status RECRUITING

Universitaire Ziekenhuizen Leuven

Leuven, , Belgium

Site Status NOT_YET_RECRUITING

Division of Cardiac Surgery, University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status RECRUITING

University Health Network

Toronto, Ontario, Canada

Site Status NOT_YET_RECRUITING

Jilin Heart Hospital

Jilin, Jilin, China

Site Status RECRUITING

Leipzig Heart Institute GmbH

Leipzig, Saxony, Germany

Site Status RECRUITING

Robert-Bosch-Hospital

Stuttgart, , Germany

Site Status NOT_YET_RECRUITING

Apollo Hospital, Bangalore

Bangalore, Karnataka, India

Site Status RECRUITING

Manipal Hospitals

New Delhi, National Capital Territory of Delhi, India

Site Status NOT_YET_RECRUITING

Tokyo Bay Urayasu Ichikawa Medical Center

Urayasu, Chiba, Japan

Site Status NOT_YET_RECRUITING

National University Hospital (NUH) - Singapore

Singapore, , Singapore

Site Status RECRUITING

Far-Eastern Memorial Hospital

Taipei, , Taiwan

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada China Germany India Japan Singapore Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mary Zhang, MD, PhD

Role: CONTACT

613-696-7230

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Johannes Bonatti, MD

Role: primary

Role: backup

(412) 648-6200

Prem Rabindra, MD

Role: primary

Wouter Oosterlinck

Role: primary

Marc Ruel, MD MPH FRCSC

Role: primary

613-761-4893

Mary Zhang, MD, PhD

Role: backup

613-696-7230

Piroze Davierwala, MD

Role: primary

Role: backup

Massimo Lemma, MD

Role: primary

Julia Krebs

Role: primary

Marc Albert, MD

Role: primary

Role: backup

Sathyaki Nambala

Role: primary

Yugal Mishra, MD

Role: primary

Keita Kikuchi, MD

Role: primary

Theodoros Kofidis, MD

Role: primary

Kuan-Ming Chiu, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20180008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.